Complementary to this, clinically aggressive histopathological CRC subtypes such as the micropapillary variant of CRC or colorectal mixed adenoneuroendocrine carcinoma/neuroendocrine carcinoma (NEC) were significantly more likely to express TROP2 compared with adenocarcinomas not otherwise specified or less aggressive subtypes such as medullary‐ or adenoma‐like adenocarcinomas (p = 0.007), as were poorly differentiated carcinomas according to the WHO grade (p = 0.034, Figure 2H–L). This evidence concerns the gene TACSTD2 and colorectal carcinoma.